| For: | Vaccaro V, Bria E, Sperduti I, Gelibter A, Moscetti L, Mansueto G, Ruggeri EM, Gamucci T, Cognetti F, Milella M. First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. World J Gastroenterol 2013; 19(28): 4511-4519 [PMID: 23901226 DOI: 10.3748/wjg.v19.i28.4511] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v19/i28/4511.htm |
| Number | Citing Articles |
| 1 |
Eleonora Lucchini, Sara Pilotto, Elisa Spada, Davide Melisi, Emilio Bria, Giampaolo Tortora. Targeting the epidermal growth factor receptor in solid tumors: focus on safety. Expert Opinion on Drug Safety 2014; 13(5) doi: 10.1517/14740338.2014.904283
|
| 2 |
Ganji Purnachandra Nagaraju, Haasita Nellipudi, Chaithanya Ganji, Vaishnavi Kuppala, Swapna Priya Ganji, Seema Kumari, Batoul Farran, Mundla Srilatha, Rachael Guenter, Bassel F. El-Rayes. Pancreatic ductal adenocarcinoma: integrating molecular insights for targeted interventions. Signal Transduction and Targeted Therapy 2026; 11(1) doi: 10.1038/s41392-026-02705-5
|
| 3 |
Matias E. Valsecchi, Enrique Díaz-Cantón, Máximo de la Vega, Susan J. Littman. Recent Treatment Advances and Novel Therapies in Pancreas Cancer: A Review. Journal of Gastrointestinal Cancer 2014; 45(2) doi: 10.1007/s12029-013-9561-z
|
| 4 |
Dongqing Wang, Haitao Zhu, Yanfang Liu, Qing Liu, Xiaodong Xie, Yuepeng Zhou, Lirong Zhang, Yan Zhu, Zhijian Zhang, Zhaoliang Su. The Low Chamber Pancreatic Cancer Cells Had Stem-Like Characteristics in Modified Transwell System: Is It a Novel Method to Identify and Enrich Cancer Stem-Like Cells?. BioMed Research International 2014; 2014 doi: 10.1155/2014/760303
|
| 5 |
Monica Tang, Julia Chen, David Goldstein, Matthew Links, Sarah Lord, Ian Marschner, Robert J. Simes, Chee K. Lee. Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer. Pancreas 2019; 48(10) doi: 10.1097/MPA.0000000000001429
|
| 6 |
Panagiotis Sarantis, Alexandros Bokas, Adriana Papadimitropoulou, Evangelos Koustas, Stamatios Theocharis, Pavlos Papakotoulas, Dimitrios Schizas, Alexandros Papalampros, Evangelos Felekouras, Athanasios G. Papavassiliou, Michalis V. Karamouzis. Combinatorial Treatment of Tinzaparin and Chemotherapy Can Induce a Significant Antitumor Effect in Pancreatic Cancer. International Journal of Molecular Sciences 2021; 22(13) doi: 10.3390/ijms22137053
|
| 7 |
Deepak Chitkara, Anupama Mittal, Ram I. Mahato. miRNAs in pancreatic cancer: Therapeutic potential, delivery challenges and strategies. Advanced Drug Delivery Reviews 2015; 81 doi: 10.1016/j.addr.2014.09.006
|
| 8 |
R. E. Kast. Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness. SpringerPlus 2015; 4(1) doi: 10.1186/s40064-015-1441-5
|
| 9 |
Altaf Mohammed, Naveena Janakiram, Shubham Pant, Chinthalapally Rao. Molecular Targeted Intervention for Pancreatic Cancer. Cancers 2015; 7(3) doi: 10.3390/cancers7030850
|
| 10 |
Michele Milella, Michele Reni, Francesco Cognetti, Giampaolo Tortora, Aldo Scarpa, Carmen Nuzzo, Carlo Garufi, Davide Melisi, Emilio Bria, Sabrina Vari, Isabella Sperduti, Vanja Vaccaro. Metastatic pancreatic cancer: Is there a light at the end of the tunnel?. World Journal of Gastroenterology 2015; 21(16): 4788-4801 doi: 10.3748/wjg.v21.i16.4788
|
| 11 |
Mariarosaria Boccellino, Lucio Quagliuolo, Concetta Alaia, Anna Grimaldi, Raffaele Addeo, Giovanni Francesco Nicoletti, Richard Eric Kast, Michele Caraglia. The strange connection between epidermal growth factor receptor tyrosine kinase inhibitors and dapsone: from rash mitigation to the increase in anti-tumor activity. Current Medical Research and Opinion 2016; 32(11) doi: 10.1080/03007995.2016.1211522
|